| Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. | |
| | |
MedLine Citation:
|
PMID: 19135050 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Resveratrol pretreatment can protect the heart by inducing pharmacological preconditioning. Whether resveratrol protects the heart when applied at reperfusion remains unknown. We examined the effect of resveratrol on myocardial infarct size when given at reperfusion and investigated the mechanism underlying the effect. Isolated rat hearts were subjected to 30 min ischemia followed by 2 h of reperfusion, and myocardial samples were collected from the risk zone for Western blot analysis. Mitochondrial swelling was spectrophotometrically measured as a decrease in absorbance at 520 nm (A(520)). Resveratrol reduced infarct size and prevented cardiac mitochondrial swelling. Resveratrol enhanced GSK-3beta phosphorylation upon reperfusion, an effect that was mediated by the cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) pathway. Resveratrol translocated GSK-3beta from cytosol to mitochondria via the cGMP/PKG pathway. Further studies showed that mitochondrial GSK-3beta was co-immunoprecipitated with cyclophilin D but not with VDAC (voltage dependent anion channel) or ANT (adenine nucleotide translocator). These data suggest that resveratrol prevents myocardial reperfusion injury presumably by targeting the mPTP through translocation of GSK-3beta from cytosol to mitochondria. Translocated GSK-3beta may ultimately interact with cyclophilin D to modulate the mPTP opening. |
| | |
Authors:
|
Jinkun Xi; Huihua Wang; Robert A Mueller; Edward A Norfleet; Zhelong Xu |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, N.I.H., Extramural Date: 2008-12-24 |
Journal Detail:
|
Title: European journal of pharmacology Volume: 604 ISSN: 1879-0712 ISO Abbreviation: Eur. J. Pharmacol. Publication Date: 2009 Feb |
Date Detail:
|
Created Date: 2009-02-06 Completed Date: 2009-06-24 Revised Date: 2011-11-02 |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 111-6 Citation Subset: IM |
Affiliation:
|
Department of Anesthesiology, University of North Carolina at Chapel Hill, NC 27599, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blotting, Western Cardiotonic Agents / pharmacology*, therapeutic use Glycogen Synthase Kinase 3 / metabolism* Immunoprecipitation Male Mitochondria, Heart / drug effects, metabolism Mitochondrial Membrane Transport Proteins / metabolism* Mitochondrial Swelling / drug effects Myocardial Infarction / enzymology, metabolism, prevention & control Myocardial Reperfusion Injury / enzymology, metabolism, prevention & control* Myocytes, Cardiac / drug effects, metabolism Rats Rats, Wistar Stilbenes / pharmacology*, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
R01 HL083362-04/HL/NHLBI NIH HHS; R01HL08336/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Mitochondrial Membrane Transport Proteins; 0/Stilbenes; 0/mitochondrial permeability transition pore; 501-36-0/resveratrol; EC 2.7.11.1/glycogen synthase kinase 3 beta; EC 2.7.11.26/Glycogen Synthase Kinase 3 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in different...
Next Document: Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma.